Bi-allelic somatic mutations in the p300 gene have been identified in gastric, colon and breast cancers (primary tumours and cancer cell lines), and some of these mutations clearly result in inactivated or truncated protein products (Muraoka et al, 1996; Gayther et al, 2000; Ozdag et al, 2002). This evidence concerns the gene EP300 and cancer.